ClinicalTrials.gg
Active, not recruitingNCT04398654Updated Apr 7, 2026

Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

An interventional study of CardioMEMSTM HF sensor - pulmonary artery pressure measurement in Heart Failure, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Active, not recruiting at 36 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.

Planned enrollment
98th of 386
554 · median 161
Started
2020
with 24 others
No phase
175 of 600
37 open now
Primary completion
2025-11
later than 23 of 135 live
Registered
427th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 98th largest by planned enrollment of the 386 interventional ones that give a count, is one of 25 that started in 2020, is one of 175 with no phase, reaches primary completion later than 23 of the 135 other live ones, and was the 427th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

100 more — sign in →

All 105 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

Randomized, parallel group controlled study examines the effect of supporting the Heart failure supply through pulmonary arterial (PA) pressure measurement with the CardioMEMS™ HF system to hard endpoints, safety and quality of life. The target population consists of heart failure (HF) patients who have been predominantly in New York Heart Association (NYHA) Stage III for the past 30 days and at least once in the past 12 months for HF were admitted to hospital. All patients receive basic care, which is based on structured telephone contact (between the care center, patient and family doctor) to optimize guideline compliant therapy. In the intervention group a PA pressure sensor is (CardioMEMS™-HF Sensor) implanted. These patients are structured by specially trained non-medical personnel aftercare with additional inclusion of the PA pressure values: adjusted to the basis of the information collected in PA monitoring the therapy is optimized. The follow-up period until the primary endpoint is 12 months.

In addition, data on longtime-mortality is being collected towards the end of the study for all study participants.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consent received from the patient or a legal representative after the in-formation has been provided.
  2. ≥ 18 years of age.
  3. Predominant symptoms in Stage III in the 30-day period prior to consent to the study.
  4. Objectified HF diagnosis for more than three months.
  5. Hospitalisation within 12 months prior to inclusion due to deterioration of HF symptoms.
  6. Able to tolerate dual antiplatelet therapy or anticoagulation therapy for one month after sensor implantation
  7. Patients with reduced (LVEF) ≤40% (diagnosed within 6 months prior to inclusion) must be treated with guideline-compliant HF pharmacotherapy; if one class of guideline-compliant medication is not tolerated, appropriate documentation must be supplied; patients must receive and tolerate at least one class of guideline-compliant medication; if no guideline-compliant medication is tolerated at all, the patient may not participate in the study.
  8. In patients with preserved LVEF (>40%; diagnosed within 6 months prior to inclu-sion) comorbidities must be treated in accordance with guideline-compliant medi-cation.
  9. Chest circumference (measured at axillary level) of less than 165 cm if >35 kg/m2.
  10. Willing and mentally and physically able to meet the requirements for follow-up and long-term basic care (this includes the long-term willingness of the patient, and of their relatives where relevant, to participate in PA pressure-based monitor-ing).
  11. Appropriate domestic situation, defined as being accessible by telephone (via fixed or mobile network) .

Exclusion criteria

Exclusion criteria:

  1. Enrolment in another study with an active treatment arm.
  2. Severe cardiovascular event (e.g. myocardial infarction, open heart surgery, stroke, CRT implantation) in the 2 months prior to admission
  3. Therapy- heart failure in ACC/AHA stage D or new therapies that have taken place or are planned in the next 12 months (e.g. implantation of a left ven-tricular assist system / transplantation)
  4. Active infection.
  5. History of recurrent (>1 episode) pulmonary embolism and/or deep vein throm-bosis.
  6. Continuous or intermittent chronic inotropic therapy.
  7. Estimated (eGFR) \<25 ml/min
  8. (according to the study physician's assessment) \<12 months.
  9. Severe, unrepaired congenital heart defect that would prevent implantation of the sensor.
  10. Severe valve vitium with planned intervention in the next 3 months
  11. Presence of a mechanical right heart valve.
  12. Mental disorder that presumably (in the opinion of the study physician) has a negative impact on patient compliance or consent.
  13. Failure of the coordinating physician to approve if the patient is enrolled in an HF disease management program or comparable case management program.
  14. Women of childbearing age with a positive pregnancy test at the time of inclusion
  15. For the intervention group: Preliminary investigations have shown that the diameter of the pulmonary artery branch intended for implantation is \<7 mm
  16. The patient has private health insurance
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
554 participants (estimated)

Study arms

  • No intervention
    Control Group

    Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.

  • Active comparator
    Intervention Group

    As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.

    Device: CardioMEMSTM HF sensor - pulmonary artery pressure measurement

Interventions

  • DeviceCardioMEMSTM HF sensor - pulmonary artery pressure measurement

    CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint: composite of unplanned HF-related rehospitalisations and all-cause death

    Composite endpoint of number of unplanned HF-related rehospitalisations or all-cause death

    Time frame: 12 months

  2. Primary safety endpoint: device-related complications

    Rate of Device / System related complications

    Time frame: 12 months

  3. Co-primary safety endpoint: sensor failure

    Rate of sensor failures

    Time frame: 12 months

Secondary outcomes

  1. Major secondary endpoint: changes in disease-related quality of life

    Change in quality of life score after 6 and 12 month measured by Kansas City Cardiomyopathy questionnaire. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: 6 and 12 months

  2. Changes in generic health-related quality of life

    Change in Quality of Life score after 6 and 12 month measures by EQ-5D questionnaire. The EQ-5D-5L descriptive system comprises the five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to /extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension (1 - 5, where higher scores indicate more severe problems). The EQ VAS records the respondent's overall current health on a vertical visual analogue scale (0-100), where the endpoints are labelled 'The best health you can imagine - 100' and 'The worst health you can imagine - 0'. The EQ VAS provides a quantitative measure of the patient's perception of their overall health.

    Time frame: 6 and 12 months

  3. HF-related mortality

    Rate of HF-related mortality

    Time frame: 12 months

  4. Cardiovascular Mortality

    Rate of cardiovascular mortality

    Time frame: 12 months

  5. All-cause Mortality

    Rate of all-cause mortality

    Time frame: 12 months

  6. Unplanned HF-related hospitalizations

    Rate of HF-related hospitalisations

    Time frame: 12 months

  7. Unplanned cardiovascular-related hospitalizations

    Rate of cardiovascular-related hospitalisations

    Time frame: 12 months

  8. Unplanned all-cause hospitalizations

    Rate of all-cause hospitalisations

    Time frame: 12 months

  9. Unplanned hospitalizations, other

    Number of days alive and out of hospital

    Time frame: 12 months

  10. Non-serious Adverse Events

    Rate of non-serious adverse events

    Time frame: 12 months

  11. Serious Adverse Events

    Rate of serious adverse events

    Time frame: 12 months

  12. Symptoms of heart failure

    Patient-reported symptoms of heart failure, measured by of the KCCQ Symptoms Score

    Time frame: 12 months

  13. Longterm-mortality

    All-cause death over the entire duration of the study

    Time frame: From date of randomization of the first patient until date of study termination of the last patient (observation time: between 12 and up to 62 months)

07

Study locations

36 sites
08

References and documents

Publications

  • Stork S, Bernhardt A, Bohm M, Brachmann J, Dagres N, Frantz S, Hindricks G, Kohler F, Zeymer U, Rosenkranz S, Angermann C, Assmus B. Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial. Clin Res Cardiol. 2022 Nov;111(11):1245-1255. doi: 10.1007/s00392-022-01987-3. Epub 2022 Mar 4. PubMed 35246723 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2025, 61 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 61 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 21, 2020
StartActual
Oct 2, 2020
Primary completionActual
Nov 25, 2025
CompletionEst.
Dec 9, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04398654
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Oct 2, 2020
Primary completion
Nov 25, 2025
Completion
Dec 9, 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Stefan Störk, MD
principal investigator · Wuerzburg University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion